|
|
Article: MedPointe to Partner Newly Approved ZOMIG(R) (Zolmitriptan) Nasal Spray; AstraZeneca adds new, fast-acting dosage form to US migraine franchise marketed by MedPointe.
- Article from:
- PR Newswire
- Article date:
- October 1, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SOMERSET, N.J., Oct. 1 /PRNewswire/ -- MedPointe Inc., the specialty pharmaceutical company, has learned that AstraZeneca has received FDA approval of its new fast-acting migraine therapeutic, ZOMIG(R) (zolmitriptan) Nasal Spray (5.0mg), for the acute treatment of migraine with or without aura in adults. The nasal spray formulation is the newest addition to the ZOMIG product line, joining the conventional ZOMIG(R) (zolmitriptan) Tablets and the ZOMIG-ZMT(R) (zolmitriptan) Orally Disintegrating Tablets. As previously announced, beginning January 1, 2004, MedPointe will assume full responsibility in the U.S. for all ZOMIG(R) franchise sales, sales transactions, marketing, ...